Animas Looks Forward To Continuous Glucose Monitoring As Market Crowds
This article was originally published in The Gray Sheet
Executive Summary
Animas' hoped-for launch of the GlucoWatch G3 continuous blood glucose monitoring system in the first half of 2006 will depend upon resolution of issues cited in a February warning letter from FDA
You may also be interested in...
Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
Medtronic’s Guardian “Real-Time” Glucose Monitor Receives FDA Approval
FDA approval of the Guardian RT continuous glucose monitoring system bodes well for the regulatory success of an integrated insulin pump-glucose monitoring product, Medtronic says